Jul 20, 2019 Last Updated 10:53 AM, Jul 6, 2019

Search in the Research Units

Published in Research Units

Primario
U.O.C. Neurologia e Centro Regionale Hub Sclerosi Multipla
Istituto "G. Giglio" di Cefalù (PA)


Collaboratori 
Gaetano VItello, aiuto
Graziella Callari, aiuto
Barbara Palmeri, aiuto
Francesca Ruscica, aiuto
Maria Andriolo, biologa

Contrada Pietrapollastra s.n.c.
90015 Cefalù (PA) - Italia
Tel. 0921-920340
Fax 0921-920405
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.neuroimmunology.it


Keywords su ambiti di competenza
Epidemiologia, trials clinici


Pubblicazioni U.O.C. Neurologia - Cefalù (2011 – 2015)

  1. Ghezzi A, Grimaldi LME, Marrosu MG, Pozzilli C, Comi G, Bertolotto A, Troiano M, Gallo P, Capra R, Centonze D, Millefiorini E, Sotgiu S, Brescia Morra V, Amato MP, Lugaresi L, Mancardi G, Caputo D, Montanari E, Provinciali L, Durelli L, Bergamaschi R, Bellantonio P, Tola MR, Cottone A, Savettieri L, Tedeschi G e Gruppo di Studio SM-SIN. Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group - Italian Neurological Society. Neurol. Sci. 2011;32:351-358 (I.F.: 1.495)
  2. Mancardi GL, Tedeschi G, Amato MP, D’Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LME, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L. Three years of experience: the Italian registry and safety data update. Neurol. Sci. 2011;31:S295-S297 (I.F.: 1.495)
  3. Sangalli F, Moiola L, Bucello S, Annovazzi P, Rizzo A, Radaelli M, Vitello G, Grimaldi LME, Ghezzi A, Martinelli V, Comi G. Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study. Neurol. Sci. 2011;31:S299-S302 (I.F.: 1.495)
  4. Smolders J, Hupperts R, Barkhof F, Grimaldi LME, Holmoy T, Killestein J, Rieckmann P, Schluep M, Vieth R, Hostalek U, Ghazi-Visser L, Beelke M, on behalf of the SOLAR study group. Efficacy of Vitamin D3 as Add-on Therapy in Patients with Relapsing–Remitting Multiple Sclerosis Receiving Subcutaneous Interferon Beta-1a: A Phase II, Multicentre, Double-blind, Randomized, Placebo-Controlled Trial. J. Neurol Sci. 2011;311:44-49. doi: 10.1016/j.jns.2011.04.013. Epub 2011 May 28 (I.F.: 2.243)
  5. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C, on behalf of the COGIMUS Study Group. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult. Scler. 2011;17:991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18 (I.F.: 4. 472)
  6. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Trojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G, for The Italian Mitoxantrone Group. Acute myeloid leukemia in italian patients multiple with sclerosis treated with mitoxantrone. Neurology 2011;77:1887-1895. doi: 10.1212/WNL.0b013e318238ee00. Epub 2011 Nov 9 (I.F.: 8.303)
  7. Bastianello S, Giugni E, Amato MP, Tola MR, Trojano M, Galletti S, Luccichenti G, Quarantelli M, Picconi O, Patti F, on behalf of the COGIMUS study group. Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) study. BMC Neurol. 2011;11:125. doi: 10.1186/1471-2377-11-125 (I.F.: 2.486)
  8. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S and Grimaldi LME; on behalf of the COGIMUS study group. Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II). Qual Life Res. 2012 Sep;21(7):1111-21. doi: 10.1007/s11136-011-0021-6. Epub 2011 Sep 28 (I.F.: 2.864)
  9. Marino Gammazza A, Bucchieri F, Grimaldi LME, Conway de Macario E, JL Macario AJL, Zummo F, Cappello F. The molecular anatomy of human Hsp60 and its similarity with that of bacterial orthologus and acetylcholine receptor reveal a potential pathogenetic role of anti-chaperonin immunity in myasthenia gravis. Cell. Mol. Neurobiol. 2012;32:943-947. doi: 10.1007/s10571-011-9789-8. Epub 2012 Jan 19 (I.F.: 2.201)
  10. Grimaldi L, Barkhof F, Beelke M, Burton J, Holmoy T, Hupperts R, Killestein J, Rieckmann P, Schluep M, Smolders J; on behalf of the SOLAR study group. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2012;78:841. doi: 10.1212/01.wnl.0000413180.13413.ce (I.F.: 8.303)
  11. Grimaldi LME, Prosperini L, Vitello G, Borriello G, Fubelli F, Pozzilli C. MRI-based analysis of natalizumab therapeutic window in multiple sclerosis. Mult. Scler. 2012;18:1337-9 doi: 10.1177/1352458512439438. Epub 2012 Mar 2 (I.F.: 4.472)
  12. Laroni A, Giacomazzi CG, Grimaldi LME, Gallo P, Sormani MP, Bertolotto A, McDermott JL, Gandoglia I, Martini I, Vitello G, Rinaldi F, Barzon L, Militello V, Pizzorno M, Bandini F, Capello E, Palù G, Uccelli A, Mancardi GL, Varnier OE. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J. Neuroimmune Pharmacol. 2012;7:665-672. doi: 10.1007/s11481-012-9366-z. Epub 2012 May 16 (I.F.: 3.172)
  13. Ghezzi A, Annovazzi P, Cocco E, Coarelli G, Lugaresi A, Rovaris M, Patti F, Capello E, Rodegher ME, Moiola L, Malucchi S, Salemi G, De Rossi N, Provinciali L, Perini P, Bergamaschi R, Scarpini E, Lus G, Gallo A, Tola MR, Amato MP, Rottoli MR, Bianchi A, Comi G and the MS Study Group-Italian Society of Neurology. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neurol. Sci. 2013;9:1633-7. doi: 10.1007/s10072-013-1300-5. Epub 2013 Jan 25. (I.F.: 1.495)
  14. Ghezzi A, Annovazzi P, Amato MP, Capello E, Cavalla P, Cocco E, Falcini M, Gallo A, Patti F, Perini P, Rodegher ME, Rovaris M, Rottoli MR, Comi G and the MS Study Group-Italian Society of Neurology. Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Mult Scler. 2013;7:961-3. doi: 10.1177/1352458513475491. Epub 2013 Feb 4 (I.F.: 4.472)
  15. Ghezzi A, Pozzilli C, Grimaldi LME, Moiola L, Brescia Morra V, Lugaresi A, Lus G, Rinaldi F, Rocca MA, Trojano M, Bianchi A, Comi G, Filippi M and the Italian MS Study Group. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases. Mult. Scler. 2013;8:1106-12. doi: 10.1177/1352458512471878. Epub 2013 Feb 11. (I.F.: 4.472)
  16. Patti F, Morra VB, Amato MP, Trojano M, Bastianello S, Tola MR, Cottone S, Plant A, Picconi O; COGIMUS Study Group. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013 Aug 30;8(8):e74111. doi: 10.1371/journal.pone.0074111. eCollection 2013 (I.F.: 3.534)
  17. Comi G, Battaglia MA, Bertolotto A, Del Sette M, Ghezzi A, Malferrari G, Salvetti M, Sormani MP, Tesio L, Stolz E, Zaratin P, Mancardi G and the CoSMo Collaborative Study Group. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult. Scler. 2013;11:1508-17. doi: 10.1177/1352458513501231. Epub 2013 Sep 6 PMID: 24126064 (I.F.: 4.472)
  18. Sorosina M, Brambilla P, Clarelli F, Barizzone N, Lupoli S, Guaschino C, Osiceanu AM, Moiola L, Ghezzi A, Coniglio G, Patti F, Mancardi G, Manunta P, Glorioso N, Guerini FR, Bergamaschi R, Perla F; PROGRESSO; PROGEMUS, Martinelli V, Cusi D, Leone M, Comi G, D'Alfonso S, Martinelli-Boneschi F. Genetic burden of common variants in progressive and bout-onset multiple sclerosis. Mult. Scler. 2013 Nov 28. [Epub ahead of print] PMID: 24277324 (I.F.: 4.472)
  19. Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Troiano M, Zaffaroni M, Malucchi S. Guidelines on the clinical use of the detection of neutralizing antibodies (NAbs) to IFN beta in Multiple Sclerosis therapy: report of the Italian Multiple Sclerosis Study group. Neurol Sci. 2014;35:307-16 doi: 10.1007/s10072-013-1616-1. Epub 2013 Dec 29. PMID: 24374787 (I.F.: 1.495)
  20. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson T, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, and O'Connor P; for the TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult. Scler. 2014;20:705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14. PMID: 24126064 (I.F.: 4.472)
  21. Bertolotto A, Capobianco M, Amato MP, Capello E, Capra R, Centonze D, Di Ioia M, Gallo A, Grimaldi L, Imberti L, Lugaresi A, Mancinelli C, Marrosu MG, Moiola L, Montanari E, Romano S, Musu L, Paolicelli D, Patti F, Pozzilli C, Rossi S, Salvetti M, Tedeschi G, Tola MR, Troiano M, Zaffaroni M, Malucchi S. Erratum to: Guidelines on the clinical use of the detection of neutralizing antibodies (NAbs) to IFN beta in Multiple Sclerosis therapy: report of the Italian Multiple Sclerosis Study group. Neurol. Sci. 2014 Feb 2; PMID: 24487700 (I.F.: 1.410)
  22. Guaschino C, Esposito F, Liberatore G, Colombo B, Annovazzi P, D’Amico E, Cavalla P, Capello E, Capra R, Galimberti D, Tedeschi G, Grimaldi L, PROGRESSO Group, PROGEMUS GROUP, Leone M, D’Alfonso S, Martinelli V, Comi G, Martinelli-Boneschi F. Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis. Neurol. Sci. 2014;35:789-91 doi: 10.1007/s10072-014-1650-7. Epub 2014 Feb 11 PMID: 24514917 (I.F.: 1.410)
  23. Grimaldi LME, Zappalà G, Castellano A, Iemolo F, Ruggieri S, Bruno G, Paolillo A. A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects. J. Neuroinflammation 2014 Feb 13; doi:10.1186/1742-2094-11-30; PMID: 24524367 (I.F.: 4.351)
  24. Bravatà V, 
Minafra L, 
Callari G, 
Gelfi C, Grimaldi LM. Analysis of thiamine transporter genes in sporadic beriberi: a case report. Nutrition. 2014 Apr 30(4):485-8. doi: 10.1016/j.nut.2013.10.008. Epub 2013 Oct 19. PMID: 24607307 (I.F.: 2.859)
  25. Tamburo E, Varrica D, Dongarrà G, Grimaldi LME. Trace Elements in scalp hair samples from patients with relapsing-remitting multiple sclerosis. PLoS One. 2015 Apr 9;10(4):e0122142. doi: 10.1371/journal.pone.0122142. eCollection 2015. PMID: 25856388 [PubMed - in process] PMCID: PMC4391939 (I.F.: 3.534)
  26. Barizzone N, Zara I, Sorosina M, Lupoli S, Porcu E, Pitzalis M, Zoledziewska M, Esposito F, Leone M, Mulas A, Cocco E, Ferrigno P, Guerini FR, Brambilla P, Farina G, Murru R, Deidda F, Sanna S, Loi A, Barlassina C, Vecchio D, Zauli A, Clarelli F, Braga D, Poddie F, Cantello R, Martinelli V, Comi G, Frau J, Lorefice L, Pugliatti M, Rosati G, the PROGEMUS Group, the PROGRESSO Group, Melis M, Marrosu MG, Cusi D, Cucca F, Martinelli Boneschi F, Sanna S, D’Alfonso S. The burden of Multiple Sclerosis variants in continental Italians and Sardinians. Mult. Scler. 2015. (I.F.: 4.472) In press

  Back to the Research Units index

Last modified on Friday, 22 January 2016 10:37
More in this category: Bonetti Bruno »

Registered area

Thanks to the support of
merck serono biogen sanofi

Conferences & Courses

17° Corso CRNI Viva la differenza: sesso e neuroimmunologia

March 7-10, 2018 
Bergamo - Bergamo Science Center

READ MORE

Encefaliti Autoimmuni e Malattie Demielinizzanti Atipiche

16 febbraio 2018
Aula Magna Giorgio De Sandre
POLICLINICO UNIVERSITARIO G.B. ROSSI - Verona

READ MORE

JNIInternational Brain Research Organization
Bringing Neuroscience to the World
JNIJournal of Neuroimmunology
Studies on all branches of neurosciences covering both research and clinical problems of neuroscientific interest.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. To find out more about the cookies we use and how to delete them, see our Cookie Policy